Novartis chief stands firm on Alcon bid
Novartis
Good news for Merck’s ( NYSE: MRK ) HIV drug franchise. The company’s Isentress drug fought off the virus as well as older drugs did, when used as start-up therapy in combination with Abbott Laboratories’ ( NYSE: ABT ) Kaletra treatment. It’s the sort of research that could affect…
Johnson & Johnson ( NYSE: JNJ ) says it’s been subpoenaed by a federal grand jury and is cooperating in an investigation into the series of high-profile recalls of its consumer drugs. And it’s facing other legal actions stemming from those recalls, including lawsuits against its McNeil Consumer Healthcare…
Yet more proof that disclosure is way better than exposure: One of the Avandia advisory panel members is a paid speaker for GlaxoSmithKline ( NYSE: GSK ), which makes the diabetes drug. But that information was never given to the committee or to the public–and the FDA is investigating….
Welcome to FiercePharma ‘s look at the most intriguing logos in pharma and biotech. Big money is spent on creating memorable images that convey a sense of the companies business, but sometimes the resulting designs leave consumers scratching their heads.
Novartis delivered a strong performance in the second quarter of 2010 – with the rapid expansion of recently launched products and important regulatory approvals achieved for new medicines – as the Group made progress on its agenda on innovation, growth and productivity.
Original Source of Novartis delivers strong financial performance…
Bayer Schering Pharma AG, Germany, has entered into a research collaboration agreement with The People’s Liberation Army General Hospital (301 Hospital) in Beijing, China.
Original Source of Bayer Schering Pharma enters strategic partnership with Hospital in China
Australia’s Sigma Pharmaceuticals ( SIP.AX ) has received three bids for its Herron drugs arm and three bids for its Orphan Australia drugs business, as it seeks an improved bid for the entire company from South Africa’s Aspen Pharmacare ( APNJ.J ). Report
Original Source of With Aspen circling,…
Who’s the Big Kahuna of HIV drugs? If you said GlaxoSmithKline ( NYSE: GSK ) or Abbott Laboratories ( NYSE: ABT ), you’re wrong. It’s Gilead Sciences ( NASDAQ: GILD ), at least according to sales figures compiled by Reuters . Gilead drugs occupy the top two slots in…
Two generics makers have received some bad news from court. Teva Pharmaceutical Industries ( NASDAQ: TEVA )